Table 1.

Demographics and neuropsychological performance.

	CN (n = 22)	SCD (n = 22)	MCI (n = 18)	P value	Post-hoc (P < 0.05)	N
Age (years)	69.1 (7.7)	68.9 (7.6)	71.3 (9.3)	ns	ns	22/22/18
Sex (male, female)	4, 18	8, 14	8, 10	ns	ns	22/22/18
Education (years)	17 (2.3)	17.1 (2.7)	16.4 (2.8)	ns	ns	21/22/18
Tau PET positive (−, +) †	17, 5	18, 4	6, 12	n/a	n/a	22/22/18
Aβ PET positive (−, +) ‡	20, 2	15, 7	6, 8	n/a	n/a	22/22/14
APOE ε4 positive (−, +)	18, 4	16, 6	7, 11	n/a	n/a	22/22/18
RAVLT - immediate recall	46.7 (9.4)	44.5 (7)	30.5 (7.4)	< 0.001	CN,SCD > MCI	18/20/17
RAVLT - delayed recall	10.2 (2.7)	9 (2.7)	2.6 (3)	< 0.001	CN,SCD > MCI	20/21/17
MoCA total scrore	27.3 (2.1)	25.9 (2.2)	21.3 (3.5)	< 0.001	CN,SCD > MCI	22/21/17
CDR - sum of boxes	0.1 (0.4)	0.2 (0.5)	1.8 (1.3)	< 0.001	CN,SCD < MCI	22/21/18
CCI - self (12 items)	15.4 (2.3)	26.6 (5.5)	35.2 (10.6)	< 0.001	CN < SCD < MCI	21/21/17

Abbreviations: Aβ, amyloid-β; APOE, apolipoprotein E; RAVLT, Rey Auditory Verbal Learning Test; MoCA, Montreal Cognitive Assessment; CDR, Clinical Dementia Rating scale; CCI, Cognitive Change Index; CN, cognitively normal; MCI, mild cognitive impairment; SCD, subjective cognitive decline.

^†Tau positivity: (+) = SUVR ≥ 1.23; SUVR = standard uptake value ratio.

^‡Amyloid positivity: (+) = [18F]Florbetapir SUVR ≥ 1.1 or [18F]Florbetaben SUVR ≥ 1.2.